Literature DB >> 29517927

Modulations in extracellular calcium lead to H+-ATPase-dependent acid secretion: a clarification of PPI failure.

Alice Miriam Kitay1,2, Marie-Therese Schneebacher1, Anne Schmitt1, Katharina Heschl1, Sascha Kopic1,3, Tariq Alfadda1, Abrar Alsaihati1, Alexander Link2, John Peter Geibel1,3.   

Abstract

The H+,K+-ATPase was identified as the primary proton secretory pathway in the gastric parietal cell and is the pharmacological target of agents suppressing acid secretion. Recently, we identified a second acid secretory protein expressed in the parietal cell, the vacuolar H+-ATPase (V-type ATPase). The aim of the present study was to further characterize H+-ATPase activation by modulations in extracellular calcium via the calcium sensing receptor (CaSR). Isolated gastric glands were loaded with the pH indicator dye BCECF-AM [2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester] to measure intracellular pH. Experiments were conducted in the absence of sodium and potassium to monitor H+-ATPase-specific transport activity. CaSR was activated with the calcimimetic R568 (400 nM) and/or by modulations in extracellular Ca2+. Elevation in calcium concentrations increased proton extrusion from the gastric parietal cell. Allosteric modification of the CaSR via R568 and calcium increased vacuolar H+-ATPase activity significantly (ΔpH/minlowCa2+(0.1mM) = 0.001 ± 0.001, ΔpH/minnormalCa2+(1.0mM) = 0.033 ± 0.004, ΔpH/minhighCa2+(5.0mM) = 0.051 ± 0.005). Carbachol significantly suppressed calcium-induced gastric acid secretion via the H+-ATPase under sodium- and potassium-free conditions. We conclude that the V-type H+-ATPase is tightly linked to CaSR activation. We observed that proton pump inhibitor (PPI) exposure does not modulate H+-ATPase activity. This elevated blood calcium activation of the H+-ATPase could provide an explanation for recurrent reflux symptoms while taking a PPI therapy. NEW & NOTEWORTHY This study emphasizes the role of the H+-ATPase in acid secretion. We further demonstrate the modification of this proton excretion pathway by extracellular calcium and the activation of the calcium sensing receptor CaSR. The novelty of this paper is based on the modulation of the H+-ATPase via both extracellular Ca (activation) and the classical secretagogues histamine and carbachol (inactivation). Both activation and inactivation of this proton pump are independent of PPI modulation.

Entities:  

Keywords:  acid secretion; gastric gland; parietal cells; proton pumps; stomach

Mesh:

Substances:

Year:  2018        PMID: 29517927     DOI: 10.1152/ajpgi.00132.2017

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  4 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

Authors:  Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

2.  Induction of Secretagogue Independent Gastric Acid Secretion via a Novel Aspirin-Activated Pathway.

Authors:  Alice Miriam Kitay; Florentina Sophie Ferstl; Alexander Link; John Peter Geibel
Journal:  Front Physiol       Date:  2019-10-10       Impact factor: 4.566

3.  In Pursuit of the Parietal Cell - An Evolution of Scientific Methodology and Techniques.

Authors:  Vanessa Baratta; Jason Own; Chiara Di Renzo; Jenna Ollodart; John P Geibel; Maria Barahona
Journal:  Front Physiol       Date:  2019-12-12       Impact factor: 4.566

Review 4.  Effects of acids, pepsin, bile acids, and trypsin on laryngopharyngeal reflux diseases: physiopathology and therapeutic targets.

Authors:  Yading Li; Gaofan Xu; Bingduo Zhou; Yishuang Tang; Xiaowen Liu; Yue Wu; Yi Wang; Jing Kong; Tingting Xu; Cong He; Shengliang Zhu; Xiaosu Wang; Jianning Zhang
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-12-03       Impact factor: 3.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.